BIOTECHNOLOGY


Alternative applications for OOC technology OOC technology can help oncology researchers study the impact of specific


tissue components, investigate the role of the tumor microenvironment (TME), or visualise how cancer cells behave over time when interacting with stromal and immune cells. Similarly OOC is better able to reproduce the complexity that influences cancer behavior in vivo, and appropriately model more recent advancements in cancer therapeutics than conventional in-vitro models. Similarly, OOC can help with inflammatory diseases. Inflammation plays


a role in many conditions including Alzheimers and Inflammatory Bowel Syndrome (IBS). However, modeling complex immune response in vitro can be difficult owing to the fundamental differences in the immune systems of animals and humans. OOC allows researchers to incorporate the cellular diversity seen in vivo into a tissue-specific microenvironment that more closely emulates the complex cell-cell interactions involved in inflammation in a closely controlled environment.


NON-ALCOHOLIC STEATOHEPATITIS One area of growing global concern is the metabolic disorder Non-alcoholic steatohepatitis (NASH), also known as Metabolic Dysfunction-associated Steatohepatitis (MASH). NASH is the most common form of chronic liver disease worldwide. Despite much R&D effort, there is only one approved therapeutic. This is mainly owing to the inability of traditional in-vivo approaches to accurately predicting the human response to this complex metabolic disease. CN Bio’s highly characterised and validated PhysioMimix NASH assay is comprised of primary human


a❝Although


incorporation of OOC technologies into drug discovery workflows.


hepatocytes, stellate and Kupffer cells that form 3D microtissues capturing key stages of disease progression, intracellular fat accumulation, inflammation and fibrosis. The OOC model supports development of drugs targeting NASH by enabling the precise mechanistic effects of drug efficacy to be uncovered.


nimal models


capture the complexity of a full organism, organ-on-a- chip technology demonstrates how a disease mechanism, or the effects of a drug, will differ in a human setting


BRIDGING THE GAP BETWEEN HUMANS AND ANIMALS Whereas animal models capture the complexity of a full organism, OOC demonstrates how a disease mechanism, or the effects of a drug, will differ in a human setting. The combination of the two gives a much broader preclinical insight into a drug’s potential. In conjunction with the PhysioMimix OOC, CN Bio’s product and service portfolio offer flexible solutions to researchers to fast-track the


AN ‘IN A BOX’ SOLUTION FROM CN BIO The company’s ‘in-a-box’ solution provides a straightforward and quick route to recreating its industry-proven models and assays, and through its Contract Research Services (CRS), the team can tailor each experimental design to deliver unique human-translatable insights and actionable data within weeks, while saving significant time and cost versus animal studies. In December 2023, the company announced its CRS had supported the characterisation of a NASH drug candidate targeting human metabolism. As metabolism in mice is very different from human, OOC offered a path forward. Compound efficacy data derived using this NASH assay was used to support the initiation of Inipharm’s Phase 1 clinical trial for INI-822. The submission represents the first example of an OOC provider’s data supporting the clinical progression of a drug for a complex metabolic liver disease and demonstrates the transformative potential of these models to provide human-relevant insights within preclinical programs. Looking to the future, the body of evidence demonstrating OOC’s superior performance versus traditional approaches is destined to continue growing since these technologies are in a unique position to help pave the way for more much-needed therapeutics to progress into the clinic, and beyond. n


For more information visit https://cn-bio.com/


OOC results compared with other prevalent techniques www.scientistlive.com 39


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60